Literature DB >> 15730088

Clinical spectrum of herpes zoster in HIV-infected versus non-HIV infected patients in Benin City, Nigeria.

A N Onunu1, A Uhunmwangho.   

Abstract

BACKGROUND: Herpes zoster is due to reactivation of the varicella-zoster virus (VZV) at the sensory nerve ganglia. Some reports indicate that there might be differences in the pattern of presentation of herpes zoster in HIV infected patients. The objective of this study therefore, is to compare the clinical spectrum of herpes zoster in HIV-infected versus non-HIV infected patients. STUDY
DESIGN: In this prospective study all patients presenting with clinical features of Herpes zoster had serological test (ELISA) for Human immunodeficiency viral (HIV) antibodies done and confirmed by the Double/Triple test algorithm. They were examined clinically to determine the dermatome(s) involved, the severity of the disease and the presence of any complication. The patients were categorized according to their HIV-status for the purpose of statistical analysis.
RESULTS: Fifty-two out of the seventy-three patients seen during the study period were evaluated: 22 male (42.3 %) and 30 female (57.7 %) patients. Thirty-six (69.2 %) patients were HIV-positive while 16 (30.8%) were HIV-negative. The age distribution of the patients was bimodal; the mean age of patients in the HIV-positive group was 36.1+/-16.14 years while that of the HIV-negative group was 56.3+/-17.51 years. Multidermatomal involvement, affectation of the Trigeminal nerve dermatome and the presence of systemic symptoms such as fever and weakness correlated significantly with the presence of HIV infection. Mean times to cessation of new vesicle formation, crusting, and resolution of zoster-associated pain were also significantly longer in the HIV-positive patients. There were no statistically significant differences in the incidence of post-herpetic neuralgia, keloids, and bacterial super-infection in both groups.
CONCLUSION: Herpes zoster was generally more severe in the presence of HIV infection.

Entities:  

Mesh:

Year:  2004        PMID: 15730088     DOI: 10.4314/wajm.v23i4.28145

Source DB:  PubMed          Journal:  West Afr J Med        ISSN: 0189-160X


  5 in total

1.  Impact of Antiretroviral Therapy on the Risk of Herpes Zoster among Human Immunodeficiency Virus-Infected Individuals in Tanzania.

Authors:  Kosuke Kawai; Claudia A Hawkins; Ellen Hertzmark; Joel M Francis; David Sando; Aisa N Muya; Nzovu Ulenga; Wafaie W Fawzi
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

2.  Robust gene expression changes in the ganglia following subclinical reactivation in rhesus macaques infected with simian varicella virus.

Authors:  Nicole Arnold; Christine Meyer; Flora Engelmann; Ilhem Messaoudi
Journal:  J Neurovirol       Date:  2017-03-20       Impact factor: 2.643

3.  Recurrent herpes zoster in early childhood.

Authors:  N Poorana Ganga Devi; S Nataraja Rathinam; Ranjani Ramachandran; Soumya Swaminathan
Journal:  Indian J Pediatr       Date:  2007-08       Impact factor: 5.319

4.  Unusual formation of keloids after each episode of recurrent herpes zoster in an HIV positive patient.

Authors:  Sankha Koley; Vikrant Saoji; Atul Salodkar
Journal:  Indian J Sex Transm Dis AIDS       Date:  2009-07

5.  IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Authors:  G N Malavige; L T Rohanachandra; L Jones; L Crack; M Perera; N Fernando; D Guruge; G S Ogg
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.